Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Cancer research deal for deCode
January 23, 2006
| A version of this story appeared in
Volume 84, Issue 4
The Icelandic firm deCode Genetics has acquired Urdur, Verdandi Skuld, a privately held cancer research firm in Iceland, for $5.5 million in stock. DeCode, which has run a genetic study of the population of Iceland, says UVS will help it broaden and enhance its cancer research by adding to its population-based resources. Meanwhile, deCode Chemistry, a U.S. operation formed from deCode's 2002 acquisition of MediChem, has renewed its collaboration with Families of Spinal Muscular Atrophy on the development of small-molecule therapeutics for the spinal disease.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter